Please login to the form below
Scott Gottlieb
This page shows the latest Scott Gottlieb news and features for those working in and with pharma, biotech and healthcare.
COVID-19 vaccines against Omicron may be fast-tracked
Scott Gottlieb, now working at Pfizer but previously commissioner of the US FDA agreed, saying there was “a reasonable degree of confidence in vaccine circles that [with] at least three ... Gottlieb agreed, saying the FDA was familiar with the mRNA
Latest news
-
Gilead reports remdesivir cuts risk of death in severe COVID-19 patients
Former US Food and Drug Administration (FDA) commissioner Scott Gottlieb also said that rigorous confirmation is needed to further support the data, tweeting that “this is very encouraging but needs to
-
UPDATED: Senate officially confirms Stephen Hahn as FDA commissioner
He was also backed by previous FDA commissioner Scott Gottlieb, who endorsed Sharpless as “an outstanding physician and scientist who is deeply committed to public health goals” who he hoped would
-
Mega-mergers dominate as buoyant markets lift biopharma
now former FDA commissioner Scott Gottlieb.
-
FDA will maintain the pace, vows Woodcock, but warns of skills gap
Top official unconcerned by dip in approval rate. The departure of Scott Gottlieb in April robbed the FDA of one of its most dynamic ever Commissioners, and industry observers have been ... Before Gottlieb departed earlier this year, he unveiled a new
-
Ex-FDA chief Gottlieb's quick move to pharma raises eyebrows
Will join Pfizer board. Just 83 days after leaving his Commissioner role at the FDA, Scott Gottlieb has joined the board of big pharma group Pfizer. ... We are fortunate to have D. Gottlieb join Pfizer’s Board of Directors,” said Pfizer executive
More from news
Approximately 5 fully matching, plus 46 partially matching documents found.
Latest Intelligence
-
20 for 2020 – Five pharma leaders to watch in 2020
He replaced Scott Gottlieb, who was popular with industry but resigned from the post unexpectedly last year, as well as stand-in Ned Sharpless who has now returned to his post
-
Will biosimilars ever catch on in the US?
In the early days of the Trump administration, then-FDA commissioner Scott Gottlieb made a point of clearing the way for even faster and more generic approvals, again with some apparent ... Based on those assumed savings, had all the FDA-approved
-
Encouraging signs in biomarker R&D
The timing of the withdrawal was ironic given that, in the same month, FDA Commissioner Scott Gottlieb highlighted ‘TMB as a potential biomarker for enriching clinical trials testing immunotherapies’. ... Harmonisation. Gottlieb has since resigned,
-
Streamlining clinical trials – why better data use is key
Dr Scott Gottlieb’s brief, energetic tenure as US FDA Commissioner is likely to shape agency oversight of the pharmaceutical industry for years to come, particularly in relation to clinical development. ... To embrace innovations like blockchain, as
-
Cell and gene therapy
Interest in cell and gene therapies is undeniable. In January, US FDA Commissioner Scott Gottlieb outlined policies designed to accommodate an anticipated surge in cell and gene therapy submissions. ... Gottlieb highlighted manufacture as a challenge
More from intelligence
Approximately 0 fully matching, plus 5 partially matching documents found.
Subscribe to our email news alerts
Featured jobs
- Scientific Strategy Lead, Medical Communications, UK
-
Highly competitive salary
- Vice President, Medical Communications, UK, six figure package
-
Six figure salary
- Medical Writer, MRNA/ Covid 19, Medical Communications, UK
-
Highly competitive salary
- Senior Analyst, Market Access, UK, Home based
-
Highly competitive salary
- New Omicron sub-variants cause COVID-19 cases to rise in the UK
- Sanofi Global Health unveils new nonprofit Impact brand
- Innovative Health Initiative launches first two calls for proposals to tackle ‘biggest’ health research challenges
- NHS App to revolutionise digital health and care with major digital updates by 2023
- Pfizer announces commitment to achieve Net-Zero Standard by 2040
- Novartis announces positive phase 3 trial results for advanced oesophageal cancer
- The Power of AI in Medical Education
- First evidence-based guide launched to put patients at heart of digital innovations
- FDA grants Priority Review for Biogen and Eisai’s lecanemab for early Alzheimer’s disease
- New Swiss research reveals how Omicron evades the immune system
- Evoke Kyne Named Communiqué Communications Consultancy of the Year 2021
- Michael Grela Elected President of the Society for Health Communication
- First evidence-based guide launched to put patients at heart of digital innovations
- Roche shares new positive Ocrevus data for MS patients
- FDA grants Priority Review for Biogen and Eisai’s lecanemab for early Alzheimer’s disease
- A creative awakening – how pharma is bringing innovation to the patient journey
- Country report: The healthcare market in South Korea
- European Commission approves potential new treatment for Pompe disease
PMHub
Cegedim Health Data
Cegedim Health Data provides Real World Data and Evidence services to enable advancements in patient outcomes. With a data history...
Latest intelligence
- Five big changes in the healthcare comms landscape
- The world of healthcare has changed very greatly in the five years since The Difference Collective launched. Our agile model and talented team have enabled us to keep pace with...
- Early communications in Pharma: How effective pre-approval comms delivers launch success
- What communications are required for a successful launch...
- Our Top 5 Pharma Picks From Cannes Lions
- Here are five of Art's top five pharma and healthcare picks from Cannes Lions 2022....
